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Abstract 
Haematological profiles serve as strong indicators of recovery and the safety of antimalarial drugs in children. The 
present study evaluated the safety of Artesunate + Sulphadoxine-Pyrimethamine (AT+SP) and Amodiaquine + 
Sulphadoxine-Pyrimethamine (AQ+SP) combination therapies in the treatment on thirteen different haematological 
and a biochemical parameters. The study was carried out in malaria holo-endemic settlements in northern Nigeria, 
among 313 children with uncomplicated Plasmodium falciparum malaria randomly selected, between July and 
September, 2012 using therapeutic efficacy protocols on antimalarial drugs. There were no cases of lympopenia, and 
recoveries were faster in AT+SP than AQ+SP for leucocytosis (37.5% vs 17.39%), anaemia (82.23% vs 78.03%), 
thrombocytopenia (90.13% vs 88.20%), monocytosis (30.92% vs 28.01%) and eosinophilia (31.68%) than AQ+SP 
(18.01%) in 28 days. Conversely, the recoveries from AQ+SP were higher than AT+SP for neutrophilia (32.89% vs 
38.45%), and ALT (76.31% vs 78.33%) over 28 days. In contrast, there were slight adverse effects in both drugs on 
leucopenia, thrombocytosis, neutropenia, lympocytosis and monocytopenia in the range of 1.97 - 20.50% for 
AT+SP compared to 3.29 - 11.18% for AQ+SP. Except for monocytopenia, the adverse effects due to AT+SP was 
higher compared to AQ+SP.  Both drugs could be adjudged safe based on rapid recoveries with negligible frequency 
of adverse effects. 
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1.0. Introduction 
Malaria (Italian: mala = bad, aria = air) has remained a serious health threat to over 24 million children in the 
tropics [18, 35]. Previous efforts to combat the disease were constrained by the decline in drug efficacy due to 
resistant Plasmodium strains and the drug adverse effects. Haematological response was proposed as one of the 
criteria for evaluating safety and therapeutic response [28]. The history of antimalarials is replete with cases of 
adverse effects on leucocyte [30] neutrophil [19], eosinophil [7] and red blood cells [20]. In response to drug 
resistance, combination therapy had been recommended as a veritable option and Artemether-Lumefantrine 
(coartem), Artesunate + Amodiaquine, Artesunate + Mefloquine, Artesunate + Sulphadoxine-pyrimethamine, and 
Amodiaquine + Sulphadoxine-pyrimethamine have recently been the exclusive choice of medical experts in the 
treatment of malaria[11,34, 35] and [36, 31]. Besides better efficacy drug safety is one of the greatest challenges to 
medical experts and parasitologist, the difficulty the lack of effective assessment tool and standard methodology. 
Clinical, haematological and biochemical response offers the best alternative for effective evaluation of drug safety 
in treated patients. This study evaluated the haematological safety profile of Artesunate + Sulphadoxine-
Pyrimethamine and Amodiaquine + Sulphadoxine-Pyrimethamine combination therapies in the treatment of 
uncomplicated Plasmodium falciparum malaria in children. 
2.0. Materials and methods 
2.1. Study Site 
The study took place in malaria holo-endemic settlements around Lake-Alau, Borno State, Nigeria (Lat: 120N and 
130N; Long: 110E and 130E). The peri-urban outpatient primary Health Center at Kayamla caters for 63 village 
settlements with a combined population of 114,224 heads (National Population Commission, 1991). 
2.2. Ethical clearance Recruitment Procedure 
Ethical clearance was granted by Borno State Ministry of Health and standard recruitment criteria of clinically 
apparent uncomplicated malaria, mono-infection and absence of severe malnutrition and measured axillary 
temperature (≥ 37.5 °C), parasite density (2,000 - 200,000 /μl) and packed cell volume (> 15%) were adopted for the 
study (World Health Organization, 2003). A total of 500 children suffering from malaria were enrolled out of which 
313 children that finally satisfied the inclusion criteria [35] with 161 and 152 patients in the AQ + SP and AT + SP 
treatment groups, respectively. 
2.3. Experimental Procedure 
2.3.1. Haematological  
Blood for the assessment parasite density was sampled on 0, 1, 2, 3, 4, 7, 14 and 28 by finger pricking, while the 
venipuncture sample was used for the assessment of Packed Cell Volume on days 0, 3, 7, 14 and 28 as described by 
WHO (1996). Haematological laboratory analysis was based on the methods by [32,10, 61]. 
2.3.2. White blood cell count (x109/µl): Micropipette was used to accurately measure out 20 µl of EDTA 
anticoagulated blood sample. The blood sample was then diluted in 0.38 ml which haemolyzed the red blood cell 
leaving only the stained white blood cells. White blood cell was counted microscopically under the x10 objectives 
using hand tally counter in haemotocytometer (‘Neubauer” ruled counting chamber). The total number of white 
blood cells was then divided by 2 and the figure obtained was further divided by 10 to arrive at the WBC x 109 per 
liter of blood. 
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2.3.3. Packed cell volume (PCV %): The EDTA anti-coagulated blood sample was centrifuged (Hawksley®) at 
12000 (rpm) for 5 minutes and the PCV value was then read-off using a hand held microhaematocrit reader and the 
values were expressed as percentages [6]. 
2.3.4. Platelet count (x109/µl): Micropipette was used to accurately measure out 20 µl of EDTA anticoagulated 
blood sample. The blood sample was then diluted in ammonium oxalate 10 g/l (1% w/v) which haemolyzed the red 
blood cell. Platelets in the small squares of the haemocytometer were then counted under the objectives of the 
microscope (x40) using hand tally counter. The actual platelet count was then directly reflected as the platelet count 
x 109 per liter of blood[6]. 
2.3.5. Differential leucocytes count: Thin blood film was stained for 30 - 45 minutes with 3% Giemsa for the 
assessment of differential leucocytes. The samples were microscopically examined under the ×100 objectives and 
neutrophils, lymphocytes, monocytes and eosinophils were directly counted in the field. These were expressed later 
as the percentage of the total leucocytes count equivalated to 100% [6]. 
2.4. Biochemical 
2.4.1 Alanine-amino-tranferase (ALT): Alanine-amino-transferase was quantitatively determined using Randox Kit 
(Randox Laboratories Ltd, UK) as described by [33]. Samples of the reagent blank, standard (pyruvat 57 ALT IU/l) 
and the patients’ serum were used for the assessment of the enzyme activity. The serum (0.1 ml) was mixed with 0.5 
ml of phosphate buffer solution (100 mmol/L, PH 7.4), containing the substrate L-alanine (200 mmol/L) and α-
ketoglutarate (2.0 mmol/L) and then incubated at 370C for 30 minutes. Thereafter, a solution (5 ml) sodium 
hydroxide was added and mixed thoroughly and allowed to stand for 20 minutes at 250C. The absorbance was then 
read against the reagent blank and sample blank in the spectrophotometer (Hg 546) at a wavelength of 505 nm. The 
absorbance values were then read-off against tabulated values to obtain the corresponding enzymes (ALT) activity 
in units per liter (U/l), which was recorded for days 0, 3, 7, 14 and 28 during the study. 
2.5. Randomization and treatment allocation 
 The amount of drug given was based on body weight: 
2.5.1. Group 1: Artesunate + Sulphadoxine- pyrimethamine (AT+SP) 
This group was made up of 152 children treated with the anti-malarial drug, Artesunate + Sulphadoxine- 
pyrimethamine. Each of the children orally received 4 mg∕kg body weight artesunate daily for three days and a 
combined 25 mg∕kg body weight sulphadoxine and 1.25 mg∕kg body weight pyrimethamine as single oral dose on 
the first day of treatment. 
2.5.2. Group 2: Amodiaquine + Sulphadoxine – pyrimethamine(AQ+SP) 
Amodiaquine + Sulphadoxine - pyrimethamine was orally administered to the second group of 161 children at the 
dose of 10 mg∕kg body weights of amodiaquine daily for three days and also a combined 25 mg∕kg body weight 
sulphadoxine and 1.25 mg∕kg body weight pyrimethamine as a single oral dose on the first day of treatment. Drug 
formulation, dose and treatment regiments are as shown in table 1. 
2.6. Data management and analysis 
Data collected were subjected to descriptive statistics using the analytical software Staistix Version 8.0 (Microsoft, 
2003). Frequency and percentages were computed for adverse haematological drug effects: leucocytosis and 
leucopenia (WBC), anemia (PCV), thrombocytosis and thrombocytopenia (platelets), neutrophilia and neutropenia 
(neutrophils), lympocytosis and lympopenia (lymphocytes), monocytosis and monocytopenia (monocytes), 
eosinophilia and eosinophenia (eosinophils). 
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table 1. 
Trade name Manufacturer  Generic name Dose/kg 
body wt. 
Course  
ARTESUNAT® 
  
Mekophar 
Pharmaceutical(Ho Chi 
Minh City, Vietnam) 
Artesunate 50 mg 
(Dihydroartemisinin 1,2-α-
succinate) 
4 mg  3 days 
CAMOQUIN® Pfizer (Dakar R.P., 
Senegal) 
Amodiaquine 
hydrochloride 200 mg 
10 mg 3 days 
MALCIDA® Juhel (Enugu, Nigeria) Sulphodoxine 500 mg 
Pyrimethamine 25 mg 
25 mg 1.25 
mg  
1 day 
3.0. Results 
Table 1 shows that there here were no cases of lympopenia and recovery from AT+SP was higher for anaemia 
(Table 2), thrombocytopenia (Table 3) and monocytosis (Table 6) with recovery frequencies of 92.76 - 10.53%, 
97.37 - 7.24% and 37.50 - 6.58% than from AQ+SP with 93.02 - 14.99%, 94.41 - 6.21%, 34.78 - 6.77%, 
respectively, over 28 days. Conversely, though, Table 4 indicates that recoveries from AQ+SP were higher than 
AT+SP for neutrophilia (36.18 - 3.29% vs 42.80 - 4.35%); while in Table 7, recovery from eosinophilia was 
irregular but faster in AT+SP (36.18 - 4.50%) than AQ+SP (29.81 - 11.80%) in 28 days. The results in Table 8 
similarly indicated higher recoveries in ALT from AQ+SP (83.23 - 4.97%) than AT+SP (77.63 - 1.32%). These 
translate to recoveries as faster in AT+SP than AQ+SP for leucocytosis (37.5% vs 17.39%), anaemia (82.23% vs 
78.03%), thrombocytopenia (90.13% vs 88.20%), monocytosis (30.92% vs 28.01%) and eosinophilia (31.68%) than 
AQ+SP (18.01%) in 28 days. Conversely, the recoveries from AQ+SP were higher than AT+SP for neutrophilia 
(32.89% vs 38.45%), and ALT (76.31% vs 78.33%) over 28 days. 
Result in Table 1 shows that AT+SP and AQ+SP triggered leucopenia from 9.94 - 20.50% and 3.29 - 8.55% in 
children. Similarly, Tables 3 - 6 indicated adverse effects from AT+SP and AQ+SP with upsurge in thrombocytosis 
(0 - 9.86% vs 0 - 5.5%), neutropenia (0 - 6.23% vs 0 - 3.37%), lympocytosis (0 - 1.97% vs 0 - 1.86%) and 
monocytopenia (4.61 - 7.89% vs 4.99 - 11.18%) in the respective drugs. Except for monocytopenia the adverse 
effects due to AT+SP was higher compared to AQ+SP.   
4.0.  Discussion 
Haematological profiles serve as effective drug safety indices in treated patients [1]. The present result depicts very 
high recovery in some key haematological and biochemical parameters namely, anaemia, thrombocytopenia and 
liver disorders (ALT) in 82.2%, 90.1% and 76.3% for AT + SP and 78.2%, 88.2% and 78.3% for AQ + SP, 
respectively. P. falciparum infection is believed to be a major contributory factor to the etiology of anemia in 
malaria endemic areas [23, 13]. Malaria parasites invade and exploit red blood cells during their asexual expansion 
[21] and the direct destruction of parasitized red blood cells through immune mechanisms destroys both parasitized 
and non-parasitized red cells or the suppresses the bone marrow[14, 13].  
Thrombocytopenia is identified as a key indicator of malaria (parasitaemia) in febrile patients and the report further 
drew a parallel trend in thrombocytopenia with parasitemia [5,8,15]. The trend of decreasing platelet count with 
increasing levels of parasitemia observed in this study has been previously noted for P. falciparum [22,25, 8]. The 
present study found 95.9% cases of thrombocytopenia at enrolment which concurs with the value of 93% [17] or 
89.0% [29].Similarly, [8, 24] further reported that platelet count showed the strongest association and had the 
greatest predictive power for malaria among all blood parameters.  
The present result also shows that rate of hepatic clearance was faster in patients treated with AT + SP than those 
that received AQ + SP with higher mean values at the end of 28 days. This could be mainly because Amodiaquine is 
retained longer in the liver and further stresses the liver cells resulting in an associated agranulocytosis and hepatitis 
[24]. Furthermore, [2] pointed out that liver function tests in patients disposed to drug shows the effects of drugs on 
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the liver. Abnormal liver enzyme levels may signal liver damage [27] and liver enzyme alteration may be the 
accompanying biochemical picture in patients [9]. The pathophysiology of malarial infection on liver relates to the 
sporozoites which invade hepatocytes after which merozoites are released and invade erythrocytes and the repeated 
cycles of erythrocyte invasion and rupture lead to organ dysfunction [3, 26].  
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Table 1 Adverse effects of AT + SP and AQ + SP on leucocytes (WBC x 109/L) during follow-up periods (0 – 28 days) 
Follow-up days Adverse effects AT + SP AQ + SP 
At enrolment Leucocytosis 66/152 (43.42%) 37/161 (22.98%) 
Leucopenia 5/152 (3.29%) 16/161 (9.94%) 
Day 3 Leucocytosis 30/152 (19.74%) 27/161 (16.77%) 
Leucopenia 6/152 (3.95%) 22/161 (13.66%) 
Day 7 Leucocytosis 16/152 (10.53%) 4/161 (2.48%) 
Leucopenia 9/152 (5.92%) 13/161 (8.07%) 
Day 14 Leucocytosis 14/152 (9.21%) 10/161 (6.21%) 
Leucopenia 9/152 (5.92%) 27/161 (16.77%) 
Day 28 Leucocytosis 9/152 (5.92%) 9/161 (5.59%) 
Leucopenia 13/152 (8.55%) 33/161 (20.50%) 
Reference ranges (Taha et al.,2007): Leucocytosis, > 13 x 109/L; Leucopenia, < 4.5 x 109/L  
 
 
Table 2 Adverse effects of AT + SP and AQ + SP on PCV (anaemia, %) during follow-up periods (0 – 28 days) 
Follow-up days Adverse effects AT + SP AQ + SP 
At enrolment Anaemia 141/152 (92.76%) 153/161 (93.03%) 
Day 3 Anaemia 135/152 (88.82%) 137/161 (85.09%) 
Day 7 Anaemia 87/152 (57.24%) 93/141 (57.76%) 
Day 14 Anaemia 64/152 (42.11%) 65/161 (40.37%) 
Day 28 Anaemia 16/152 (10.53%) 24/161 (14.91%) 
Reference ranges (Taha et al.,2007): PCV < 33% (Anaemic) 
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Table 3 Adverse effects of AT + SP and AQ + SP on platelets (x 109/µl) during follow-up periods (0 – 28 days) 
Follow-up days Adverse effects AT + SP AQ + SP 
At enrolment Thrombocytosis 0/152 (0%) 0/161 (0%) 
Thrombocytopenia 148/152 (97.37%) 152/161 (94.41%) 
Day 3 Thrombocytosis 0/152 (0%) 0/161 (0%) 
Thrombocytopenia 77/152 (50.66%) 65/161 (40.37%) 
Day 7 Thrombocytosis 1/152 (0.66%) 2/161 (1.24%) 
Thrombocytopenia 24/152 (15.79%) 33/161 (20.50%) 
Day 14 Thrombocytosis 1/152 (0.66%) 2/161 (1.24%) 
Thrombocytopenia 18/152 (11.84%) 22/161 (13.66%) 
Day 28 Thrombocytosis 15/152 (9.86%) 9/161 (5.59%) 
Thrombocytopenia 11/152 (7.24%) 10/161 (6.21%) 
Reference ranges (Taha et al., 2007): Thrombocytosis, > 400,000 x 109/µl;                                                    
         Thrombocytopenia, < 150,000 x 109/µl 
Table 4 Adverse effects of AT + SP and AQ + SP on neutrophils (%) during follow-up periods (0 – 28 days) 
Follow-up days Adverse effects AT + SP AQ + SP 
At enrolment Neutrophilia 55/152 (36.18%) 69/161 (42.86%) 
Neutropenia 0/152 (0%) 0/161 (0%) 
Day 3 Neutrophilia 40/152 (26.32%) 23/161 (14.86%) 
Neutropenia 0/152 (0%) 0/161 (0%) 
Day 7 Neutrophilia 19/152 (12.50%) 10/161 (6.21%) 
Neutropenia 3/152 (1.97%) 4/161 (2.84%) 
Day 14 Neutrophilia 13/152 (8.55%) 9/161 (5.59%) 
Neutropenia 4/152 (2.63%) 6/161 (3.73%) 
Day 28 Neutrophilia 25/152 (16.44%) 7/161 (4.35%) 
Neutropenia 1/152 (0.66%) 9/161 (5.59%) 
Reference ranges (Taha et al.,2007): Neutrophilia, >65%; Neutropenia, < 30% 
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Table 5  Adverse effects of AT + SP and AQ + SP on lympocytes (%) during follow- up periods (0 – 28 days) 
Follow-up days Adverse effects AT + SP AQ + SP 
At enrolment Lympocytosis 0/152 (0%) 2/161 (1.20%) 
Lympopenia 78/152 (51.32%) 96/161 (59.62) 
Day 3 Lympocytosis 1/152 (0.65%) 1/161 (0.62%) 
Lympopenia 35/152 (23.02%) 51/161 (31.67%) 
Day 7 Lympocytosis 1/152 (0.65%) 3/161 (1.86%) 
Lympopenia 21/152 (13.82%) 28/161 (17.39%) 
Day 14 Lympocytosis 3/152 (1.97%) 0/161 (%) 
Lympopenia 13/152 (8.55%) 33/161 (20.49%) 
Day 28 Lympocytosis 0/152 (0%) 0/161 (0%) 
Lympopenia 9/152 (5.92%) 23/161 (14.28%) 
Reference ranges (Taha et al., 2007): Lympocytosis, > 60%; Lympopenia, < 30% 
Table 6   Adverse effects of AT + SP and AQ + SP on monocytes (%) during follow-up periods (0 – 28 days) 
Follow-up days Adverse effects AT + SP AQ + SP 
At enrolment Monocytosis 37/152 (24.34%) 56/161 (34.78%) 
Monocytopenia 7/152 (4.61%) 8/161 (4.99%) 
Day 3 Monocytosis 24/152 (15.80%) 27/161 (16.77%) 
Monocytopenia 12/152 (7.89%) 16/161 (10.53%) 
Day 7 Monocytosis 22/152 (14.50%) 23/161 (14.29%) 
Monocytopenia 10/152 (6.57%) 18/161 (11.18%) 
Day 14 Monocytosis 24/152 (19.21%) 25/161 (15.53%) 
Monocytopenia 11/152 (7.24%) 17/161 (10.56%) 
ay 28 Monocytosis 18/152 (11.84%) 27/161 (6.77%) 
Monocytopenia 3/152 (1.97%) 8/161 (4.97%) 
Reference ranges (Taha et al.,2007): Monocytosis, > 9%; Monocytopenia, < 1% 
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Table 7 Adverse effects of AT + SP and AQ + SP on eosinophils (%) during   follow-up periods (0 – 28 days) 
Follow-up days Adverse effects AT + SP AQ + SP 
At enrolment Eosinophilia 55/152 (36.18%) 48/161 (29.81%) 
Eosinophenia 0/152 (0%) 0/161 (0%) 
Day 3 Eosinophilia 30/152 (19.74%) 49/161 (30.43%) 
Eosinophenia 0/152 (0%) 0/161 (0%) 
Day 7 Eosinophilia 31/152 (20.39%) 36/161 (22.36%) 
Eosinophenia 0/152 (0%) 0/161 (0%) 
Day 14 Eosinophilia 19/152 (12.50%) 23/161 (14.28%) 
Eosinophenia 0/152 (0%) 0/161 (0%) 
Day 28 Eosinophilia 16/152 (10.52%) 19/161 (11.80%) 
Eosinophenia 0/152 (0%) 0/161 (0%) 
Reference ranges (Taha et al.,2007): Eosinophilia, > 4%; Eosinophenia, 1 < % 
Table 8  Adverse effects of AT + SP and AQ + SP on ALT (U/L) during follow-up periods (0 – 28 days) 
Follow-up days Adverse effects AT + SP AQ + SP 
At enrolment Abnormal 118/152 (77.63%) 134/161 (83.23%) 
Day 3 Abnormal 32/152 (21.05%) 39/161 (24.22%) 
Day 7 Abnormal 23/152 (15.13%) 45/161 (27.95%) 
Day 14 Abnormal 3/152 (1.97%) 20/161 (12.42%) 
Day 28 Abnormal 2/152 (1.32%) 8/161 (4.97%) 
Reference ranges (Llorenc et al., 2006): ALT > 40 U/L (abnormal) 
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